ABS38: Add-on omalizumab significantly improves quality of life in patients with severe persistent allergic (IgE-mediated) asthma

INTRODUCTION: Patients with severe persistent allergic asthma experience frequent serious exacerbations and daily symptoms that diminish health-related quality of life (QoL). AIMS AND OBJECTIVES: To evaluate effects on QoL of add-on omalizumab, an anti-IgE therapy. Subjects and method: A pooled anal...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Prim Care Respir J
Päätekijät: Price, D., Fox, H., Surrey, K., Reisner, C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2006
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6730753/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.137
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia